• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受免疫检查点抑制剂治疗的肺癌患者中,体能状态评分预测静脉血栓栓塞的价值。

The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.

机构信息

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

West China School of Medicine, Sichuan University, Chengdu, Sichuan Province, China.

出版信息

Eur J Oncol Nurs. 2024 Apr;69:102527. doi: 10.1016/j.ejon.2024.102527. Epub 2024 Feb 5.

DOI:10.1016/j.ejon.2024.102527
PMID:38377652
Abstract

INTRODUCTION

The incidence of venous thromboembolism (VTE) is notably high in lung cancer patients, particularly among those treated with immune checkpoint inhibitors (ICIs). Previous studies have focused on the relationship between Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) and VTE risk in immune checkpoint inhibitor therapy, but available evidence is inconsistent.

METHODS

The clinical data of lung cancer patients treated with ICIs were collected and analyzed from West China Hospital between January 2018 and March 2022. ECOG PS score was measured on admission. The primary outcome was the incidence of VTE, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). Multivariate logistic regression analysis was conducted to calculate the odds ratio (OR) and 95% confidence interval (95% CI).

RESULTS

A total of 1115 lung cancer patients receiving ICIs were eligible for this study, VTE developed in 105 (9.4%) during the 12-month follow-up, of which 95 (8.5%) had DVT,14 (1.3%) had definite PE. Poor ECOG PS (PS ≥ 2) was associated with an increased risk for VTE (OR = 5.405, 95% CI = 3.067-9.525, P < 0.001), DVT (OR = 4.669, 95% CI = 2.588-8.427, P < 0.001) and PE (OR = 8.413, 95% CI = 2.565-27.600, P < 0.001) after multivariable adjustment in the study cohort.

CONCLUSION

VTE occurred in 9.4% of lung cancer patients treated with ICIs, and poor performance status was associated with an increased risk of VTE.

摘要

简介

静脉血栓栓塞症(VTE)在肺癌患者中的发病率显著较高,尤其是在接受免疫检查点抑制剂(ICI)治疗的患者中。先前的研究主要集中在东部肿瘤协作组(ECOG)表现状态(PS)与免疫检查点抑制剂治疗中 VTE 风险之间的关系,但现有证据并不一致。

方法

收集并分析了 2018 年 1 月至 2022 年 3 月在华西医院接受 ICI 治疗的肺癌患者的临床数据。入院时测量 ECOG PS 评分。主要结局是 VTE 的发生率,包括深静脉血栓形成(DVT)和肺栓塞(PE)。采用多变量逻辑回归分析计算比值比(OR)和 95%置信区间(95%CI)。

结果

共纳入 1115 例接受 ICI 治疗的肺癌患者,在 12 个月的随访期间,105 例(9.4%)发生 VTE,其中 95 例(8.5%)发生 DVT,14 例(1.3%)发生明确的 PE。较差的 ECOG PS(PS≥2)与 VTE(OR=5.405,95%CI=3.067-9.525,P<0.001)、DVT(OR=4.669,95%CI=2.588-8.427,P<0.001)和 PE(OR=8.413,95%CI=2.565-27.600,P<0.001)风险增加相关,在研究队列中进行多变量调整后。

结论

ICI 治疗的肺癌患者中 9.4%发生 VTE,较差的表现状态与 VTE 风险增加相关。

相似文献

1
The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.在接受免疫检查点抑制剂治疗的肺癌患者中,体能状态评分预测静脉血栓栓塞的价值。
Eur J Oncol Nurs. 2024 Apr;69:102527. doi: 10.1016/j.ejon.2024.102527. Epub 2024 Feb 5.
2
Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors.验证风险评估评分在预测接受免疫检查点抑制剂治疗的肺癌患者中的静脉血栓栓塞风险中的作用。
BMC Pulm Med. 2024 Oct 10;24(1):507. doi: 10.1186/s12890-024-03323-z.
3
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗肺癌患者的静脉血栓栓塞发生率和 Khorana 评分的鉴别能力。
J Thromb Thrombolysis. 2022 Aug;54(2):287-294. doi: 10.1007/s11239-022-02649-x. Epub 2022 Apr 8.
4
Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.静脉血栓栓塞症发生率及相关风险因素与晚期非小细胞肺癌患者免疫检查点抑制剂治疗。
J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-006072.
5
Comparison among different presentations of venous thromboembolism because of lung cancer.肺癌所致静脉血栓栓塞不同表现形式的比较。
Clin Respir J. 2019 Sep;13(9):574-582. doi: 10.1111/crj.13060. Epub 2019 Aug 7.
6
Long-term risk of venous thromboembolism recurrence after isolated superficial vein thrombosis.孤立性浅静脉血栓形成后静脉血栓栓塞复发的长期风险。
J Thromb Haemost. 2017 Jun;15(6):1123-1131. doi: 10.1111/jth.13679. Epub 2017 May 5.
7
The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.特发性静脉血栓栓塞患者的长期复发风险:一项观察性队列研究。
J Thromb Haemost. 2016 Dec;14(12):2402-2409. doi: 10.1111/jth.13524. Epub 2016 Nov 19.
8
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗中静脉和动脉血栓栓塞的发生率、风险因素和结局。
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
9
The Prevalence of Symptomatic Deep Venous Thrombosis and Pulmonary Embolism After Anterior Cruciate Ligament Reconstruction.前交叉韧带重建术后有症状的深静脉血栓形成和肺栓塞的患病率
Am J Sports Med. 2015 Nov;43(11):2714-9. doi: 10.1177/0363546515601970. Epub 2015 Sep 21.
10
Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study.癌症相关性肺栓塞的体能状态与长期预后:来自北陆血管栓塞癌症研究的见解
JACC CardioOncol. 2022 Nov 15;4(4):507-518. doi: 10.1016/j.jaccao.2022.07.008. eCollection 2022 Nov.

引用本文的文献

1
Venous thromboembolic complications in patients newly diagnosed with cholangiocarcinoma.新诊断胆管癌患者的静脉血栓栓塞并发症
J Thromb Thrombolysis. 2025 Apr;58(4):566-575. doi: 10.1007/s11239-025-03099-x. Epub 2025 Apr 11.
2
Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China.开发并验证一种列线图模型,用于预测接受免疫检查点抑制剂治疗的肺癌患者发生静脉血栓栓塞风险:中国的一项队列研究。
Cancer Med. 2024 Aug;13(16):e70115. doi: 10.1002/cam4.70115.
3
Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.
解析癌症免疫治疗中的调节性T细胞动态:机制、意义及治疗创新
ACS Pharmacol Transl Sci. 2024 Jul 3;7(8):2215-2236. doi: 10.1021/acsptsci.4c00156. eCollection 2024 Aug 9.